Report says COVID-19 patients respond to Gilead's remdesivir, shares surge

Gilead Sciences Inc's shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company's experimental drug remdesivir in severe COVID-19 patients.

from Reuters: Business News https://ift.tt/2RNaqoy